|
|
Search
|
Over 18,000 Health Products
At Your Fingertips=21
|
|
|
|
|
|
|
|
|
|
Friday, November 14, 2008
Peppermint Oil, Fiber Can Fight Irritable Bowel
These older treatments may sometimes work best, researchers say
By Steven Reinberg
HealthDay Reporter
(HealthDay News) -- For some patients, the best therapy for irritable bowel syndrome (IBS) may be older, cheaper drugs such as fiber, antispasmodics and peppermint oil, a new study finds.
According to researchers, these simple treatments have fallen out of favor because of the availability of newer (and more expensive) drugs, some of which have been taken off the market due to safety concerns.
But more traditional therapies should become first-line treatments in guidelines for the treatment of IBS, the experts say.
IBS can be difficult for physicians to treat, noted lead researcher Dr. Alex Ford, from McMaster University, Health Sciences Centre in Ontario, Canada.
New drugs are always being developed, but recent ones such as alosetron and tegaserod have been withdrawn, and are now only available on a restricted basis, and renzapride has not been shown to be effective, he said. On the other hand older drugs, which are cheap, safe, and in some cases available over the counter, appear to be effective in IBS.
The report is published in the Nov. 14 online edition of the
BMJ
.
As many as 45 million Americans may have IBS, the International Foundation for Functional Gastrointestinal Disorders reports. Between 60 percent and 65 percent of IBS sufferers are women.
In addition to pain and discomfort, people with IBS experience chronic or recurrent constipation or diarrhea -- or bouts of both. While the exact cause of the condition isn't known, symptoms seem to result from a disturbance in the interaction of the gut, brain and nervous system, according to the foundation.
For the study, Ford's team reviewed trials that compared IBS treatment with fiber antispasmodics and peppermint oil to a placebo or no treatment. The trials included more than 2,500 IBS patients.
The researchers found that fiber, antispasmodics and peppermint oil were effective treatments for IBS. Specifically, that meant that to prevent IBS symptoms in one patient, 11 needed to be treated with fiber, five with antispasmodics, and 2.5 with peppermint oil.
There were no serious side effects associated with any of these treatments, the researchers note.
Peppermint oil appeared to be the most effective therapy of those reviewed, the researchers found.
In trials comparing fiber with placebo, insoluble fiber such as bran was not effective. Instead, only soluble fiber, such as ispaghula husk, reduced symptoms. For antispasmodics, the most effective was hyoscine. This should be used first among antispasmodics, Ford's group advised.
Physicians, particularly those in primary care, who are being asked to take increasing responsibility for the management of IBS, should consider the use of these agents as first-line therapies for IBS, Ford said.
Dr. Roger Jones, from Kings College London and author of an accompanying journal editorial, welcomed the study.
These treatments might be slightly more effective than recently thought and they are worth trying, Jones said.
For some patients with pain and diarrhea the antispasmodics may be useful. Patients with constipation should try fiber and for other patients, peppermint oil may be helpful, Jones said.
If you have IBS which is not under reasonably good control or you are not happy with your symptom profile, you should see your primary-care doc or gastroenterologist for review and perhaps remind them that there is new evidence about the effectiveness of these traditional medicines and you would like to give it a go, Jones said.
Alternatively, if you feel sufficiently well-informed and confident, you can go do it yourself and get these treatments at the pharmacy, Jones added.
More information
For more information on IBS, visit the
U.S. National Institute of Diabetes and Digestive and Kidney Diseases
.
SOURCES: Alex Ford, M.D., McMaster University, Health Sciences Centre, Ontario, Canada; Roger Jones, M.D., Kings College London, London; Nov. 14, 2008,
BMJ
, online
|
|